Last reviewed · How we verify
Conventional antithrombotic strategy
Conventional antithrombotic strategy is a Antithrombotic agents (antiplatelet and/or anticoagulant) Small molecule drug developed by Duk-Woo Park, MD. It is currently FDA-approved for Acute coronary syndrome, Atrial fibrillation for stroke prevention, Venous thromboembolism prophylaxis and treatment.
Conventional antithrombotic strategy prevents blood clot formation through antiplatelet and/or anticoagulant agents to reduce thrombotic events.
Conventional antithrombotic strategy involves the use of standard dual antiplatelet therapy. The modality of conventional antithrombotic strategy is not specified, but it is known to be used in conditions such as coronary stenoses, atrial fibrillation, atrial flutter, atrial tachycardia, and mini-stroke.
At a glance
| Generic name | Conventional antithrombotic strategy |
|---|---|
| Sponsor | Duk-Woo Park, MD |
| Drug class | Antithrombotic agents (antiplatelet and/or anticoagulant) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This represents a standard clinical approach using established antithrombotic medications such as aspirin, clopidogrel, warfarin, or heparins to inhibit platelet aggregation or coagulation cascade activation. The strategy is used to prevent arterial and venous thromboembolism in patients at risk for myocardial infarction, stroke, or deep vein thrombosis.
Approved indications
- Acute coronary syndrome
- Atrial fibrillation for stroke prevention
- Venous thromboembolism prophylaxis and treatment
- Peripheral arterial disease
Common side effects
- Bleeding
- Gastrointestinal hemorrhage
- Intracranial hemorrhage
- Thrombocytopenia
Key clinical trials
- TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI (PHASE4)
- STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial (NA)
- Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease. (PHASE4)
- Intensified Secondary Prevention Intending a Reduction of Recurrent Events in TIA and Minor Stroke Patients (NA)
- Strategy of Early Detection and Active Management of Supraventricular Arrhythmia With Telecardiology (SETAM) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conventional antithrombotic strategy CI brief — competitive landscape report
- Conventional antithrombotic strategy updates RSS · CI watch RSS
- Duk-Woo Park, MD portfolio CI
Frequently asked questions about Conventional antithrombotic strategy
What is Conventional antithrombotic strategy?
How does Conventional antithrombotic strategy work?
What is Conventional antithrombotic strategy used for?
Who makes Conventional antithrombotic strategy?
What drug class is Conventional antithrombotic strategy in?
What development phase is Conventional antithrombotic strategy in?
What are the side effects of Conventional antithrombotic strategy?
Related
- Drug class: All Antithrombotic agents (antiplatelet and/or anticoagulant) drugs
- Manufacturer: Duk-Woo Park, MD — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome
- Indication: Drugs for Atrial fibrillation for stroke prevention
- Indication: Drugs for Venous thromboembolism prophylaxis and treatment
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing